Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects

Diabetes, Obesity and Metabolism

Volumn 10, Issue 11, 2008, Pages 1105-1113

  Becker, Reinhard H A ^a   Frick, A D ^a   Teichert, L ^a   Nosek, L ^b   Heinemann, T ^b   Heise, T ^b   Rave, K ^b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b Profil Institute for Metabolic Research   (Germany)

Author keywords

Fluctuation; Glucose clamp; Insulin glargine; Pharmacodynamics; Pharmacokinetics; Reproducibility

Indexed keywords

INSULIN GLARGINE; POLYSORBATE 20;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FIBER; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; PROTEIN FOLDING; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

EID: 54249111368     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00874.x     Document Type: Article

References (33)

1. Gerich J, Becker RH, Zhu R, Bolli GB. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 2006; 8: 237-243.
2. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 2000; 101: 2047-2052.
3. Fisman EZ, Motro M, Tenenbaum A et al. Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up. Eur J Cardiovasc Prev Rehabil 2004; 11: 135-143.
4. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
5. DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 1996; 276: 1409-1415.
6. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
7. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.
8. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46.
9. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
10. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000; 23: 813-819.
11. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
12. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000; 23: 157-162.
13. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.
14. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
15. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
16. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-196.
17. Sluzky V, Tamada JA, Klibanov AM, Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci U S A 1991; 88: 9377-9381.
18. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci 1997; 86: 517-525.
19. Lougheed WD, Albisser AM, Martindale HM, Chow JC, Clement JR. Physical stability of insulin formulations. Diabetes 1983; 32: 424-432.
20. Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R. An individual bioequivalence criterion: Regulatory considerations. Stat Med 2000; 19: 2821-2842.
21. Haidar SH, Davit B, Chen ML et al. Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 2008; 25: 237-241.
22. sanofi-aventis. Summary of Product Characteristics -LANTUS ® (insulin glargine). 2007.
23. Fieller E. Some problems in interval estimation. J Royal Stat Soc 1954; 16: 175-185.
24. Food and Drug Administration, US Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. 2003.
25. Food and Drug Administration, US Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approached to Establishing Bioequivalence. 2001.
26. Steinijans VW, Diletti E. Statistical analysis of bioavailability studies: Parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 1983; 24: 127-136.
27. Chinchilli VM, Esinhart JD. Design and analysis of intra-subject variability in cross-over experiments. Stat Med 1996; 15: 1619-1634.
28. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic. glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005; 48: 1988-1995.
29. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (LANTUS): A multiple injection study in patients with Type 1 diabetes. Diabet Med 2002; 19: 490-495.
30. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
31. Porcellati F, Rossetti P, Ricci Busciantella N et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: A double-blind, randomized, cross-over study. Diabetes Care 2007; 30: 2447-2452.
32. Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med 2006; 23: 46-52.
33. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.